Krystal Biotech, Inc. (KRYS) Balance Sheet

Retained earnings swung from a deficit of $253.3M to positive $197.9M over the ten-quarter window, which suggests the commercial VYJUVEK franchise has converted prior operating losses into a cumulative earnings base. The near-constant debt level alongside rising equity implies the expansion was self-funded, reducing the probability of near-term dilutive capital needs. Investors should monitor whether equity growth continues to be earnings-driven, since net income has been volatile quarter to quarter.

The current ratio has compressed from a peak near 10.1 in 2025Q3 toward 7.9, which may reflect growing current liabilities as commercial operations scale rather than any erosion of cash. Even a sharp drop in product revenue would leave the company with multiple years of covered obligations at current operating cost levels. The main question is how management deploys this cash, since the balance sheet currently carries more liquidity than the business requires.

Debt has declined modestly from $9.7M to $8.6M over the last five quarters, consistent with scheduled amortization rather than new borrowing. Because leverage is effectively absent, refinancing risk and covenant pressure are not material concerns based on the reported figures. This suggests the capital structure is an equity-funded platform, which makes the business less sensitive to rate environments than levered peers.

The absence of deferred revenue in most quarters implies that VYJUVEK revenue is largely recognized on delivery rather than on multi-period prepayment, limiting the visibility that a subscription-like contract base would provide. The spike in 2026Q2 may indicate a timing effect around shipments or reimbursement arrangements, though the reported figures alone cannot confirm the cause. Investors should treat forward visibility as moderate and rely more on patient persistence trends than on balance sheet deferrals.